- Home
- GBIO vs HHS Comparison
GBIO vs HHS Comparison
Compare GBIO & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- HHS
- Stock Information
- Founded
- GBIO 2016
- HHS 1923
- Country
- GBIO United States
- HHS United States
- Employees
- GBIO N/A
- HHS N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- HHS Advertising
- Sector
- GBIO Health Care
- HHS Consumer Discretionary
- Exchange
- GBIO Nasdaq
- HHS Nasdaq
- Market Cap
- GBIO 29.5M
- HHS 27.3M
- IPO Year
- GBIO 2020
- HHS N/A
- Fundamental
- Price
- GBIO $5.99
- HHS $3.69
- Analyst Decision
- GBIO Buy
- HHS
- Analyst Count
- GBIO 4
- HHS 0
- Target Price
- GBIO $10.67
- HHS N/A
- AVG Volume (30 Days)
- GBIO 70.7K
- HHS 20.9K
- Earning Date
- GBIO 11-05-2025
- HHS 11-13-2025
- Dividend Yield
- GBIO N/A
- HHS N/A
- EPS Growth
- GBIO N/A
- HHS N/A
- EPS
- GBIO N/A
- HHS N/A
- Revenue
- GBIO $21,230,000.00
- HHS $174,951,000.00
- Revenue This Year
- GBIO N/A
- HHS $6.54
- Revenue Next Year
- GBIO N/A
- HHS N/A
- P/E Ratio
- GBIO N/A
- HHS N/A
- Revenue Growth
- GBIO 61.15
- HHS N/A
- 52 Week Low
- GBIO $3.00
- HHS $3.06
- 52 Week High
- GBIO $29.10
- HHS $7.72
- Technical
- Relative Strength Index (RSI)
- GBIO 54.23
- HHS 51.90
- Support Level
- GBIO $5.51
- HHS $3.67
- Resistance Level
- GBIO $6.04
- HHS $3.83
- Average True Range (ATR)
- GBIO 0.32
- HHS 0.10
- MACD
- GBIO -0.08
- HHS 0.01
- Stochastic Oscillator
- GBIO 64.86
- HHS 60.81
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.